In our T47D/PKCα xenograft preclinical model, we reported complete tumor regression following 17β-estradiol (E2) administration [36] and subsequently determined that ERα is likely to be required for E2-triggered tumor regression. The gene discussed is PRKCA; the disease is neoplasm.